Another healthcare organization has partnered with BioIntelliSense to enable remote patient monitoring. The company’s latest customer is Jasper Health, which currently has more than 10,000 members and maintains a digital engagement platform for those diagnosed with cancer.
The Jasper platform was designed to help caregivers track patient symptoms, and to make it easier for patients to follow their treatment regimen. The partnership with BioIntelliSense will improve the quality of the data generated through the system, thanks to the use of the company’s BioSticker and BioButton wearable devices. Both the BioSticker and BioButton are FDA-certified single-use devices, and can track vital information like temperature, heart rate, respiratory rate, and body position for as much as 30 days.
The information gathered with the wearables will allow doctors to respond to adverse events more quickly, and ensure a higher level of care for Jasper clients. The Jasper platform can help people manage their medications, and connects them with doctors for live video consultations. BioIntelliSense also noted that the demand for remote care services has increased during the pandemic, and that cancer patients are in the high-risk category for COVID-19.
“This underscores the need for continuous monitoring of elevated temperature and adverse vital sign trends, along with personalized remote care guidance, to address oncology patient populations at scale,” said BioIntelliSense Co-Founder and CEO James Mault. “The ability to monitor oncology care patients for earlier detection of signs and symptoms is a key benefit of our medical-grade biosensors and analytics.”
The BioSticker is already being used to advance cancer research thanks to a strategic partnership with the Leukemia & Lymphoma Society, which is using the device to collect data during clinical trials. BioIntelliSense raised $45 million in a round of Series B funding in July, and counts AirStrip and VeeMed as some of its other recent customers.
(Originally posted on Mobile ID World)